IsoRay

Last updated
Isoray Inc.
Type Public
AMEX:  ISR
Industryhealthcare
Founded2004
Headquarters Richland, Washington
Website http://www.isoray.com

Isoray Inc. (Isoray) is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. [1] Isoray is a registered manufacturer with the FDA and holds multiple 510(k) clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu. [2]

The company went public in 2005. [3] Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354. [3]

Related Research Articles

<span class="mw-page-title-main">Caesium</span> Chemical element, symbol Cs and atomic number 55

Caesium is a chemical element with the symbol Cs and atomic number 55. It is a soft, silvery-golden alkali metal with a melting point of 28.5 °C (83.3 °F), which makes it one of only five elemental metals that are liquid at or near room temperature. Caesium has physical and chemical properties similar to those of rubidium and potassium. It is pyrophoric and reacts with water even at −116 °C (−177 °F). It is the least electronegative element, with a value of 0.79 on the Pauling scale. It has only one stable isotope, caesium-133. Caesium is mined mostly from pollucite. Caesium-137, a fission product, is extracted from waste produced by nuclear reactors. It has the largest atomic radius of all elements whose radii have been measured or calculated, at about 260 picometers.

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy, often abbreviated RT, RTx, or XRT, is a therapy using ionizing radiation, generally provided as part of cancer treatment to control or kill malignant cells and normally delivered by a linear accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

Radionuclide therapy uses radioactive substances called radiopharmaceuticals to treat medical conditions, particularly cancer. These are introduced into the body by various means and localise to specific locations, organs or tissues depending on their properties and administration routes. This includes anything from a simple compound such as sodium iodide that locates to the thyroid via trapping the iodide ion, to complex biopharmaceuticals such as recombinant antibodies which are attached to radionuclides and seek out specific antigens on cell surfaces.

<span class="mw-page-title-main">Brachytherapy</span> Type of radiation therapy

Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachy is Greek for short. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, esophageal and skin cancer and can also be used to treat tumours in many other body sites. Treatment results have demonstrated that the cancer-cure rates of brachytherapy are either comparable to surgery and external beam radiotherapy (EBRT) or are improved when used in combination with these techniques. Brachytherapy can be used alone or in combination with other therapies such as surgery, EBRT and chemotherapy.

<span class="mw-page-title-main">Nuclear medicine</span> Medical specialty

Nuclear medicine or nucleology is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear imaging, in a sense, is "radiology done inside out" because it records radiation emitting from within the body rather than radiation that is generated by external sources like X-rays. In addition, nuclear medicine scans differ from radiology, as the emphasis is not on imaging anatomy, but on the function. For such reason, it is called a physiological imaging modality. Single photon emission computed tomography (SPECT) and positron emission tomography (PET) scans are the two most common imaging modalities in nuclear medicine.

Iodine-131 is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission. See fission product yield for a comparison with other radioactive fission products. 131I is also a major fission product of uranium-233, produced from thorium.

<span class="mw-page-title-main">Caesium chloride</span> Chemical compound

Caesium chloride or cesium chloride is the inorganic compound with the formula CsCl. This colorless salt is an important source of caesium ions in a variety of niche applications. Its crystal structure forms a major structural type where each caesium ion is coordinated by 8 chloride ions. Caesium chloride dissolves in water. CsCl changes to NaCl structure on heating. Caesium chloride occurs naturally as impurities in carnallite, sylvite and kainite. Less than 20 tonnes of CsCl is produced annually worldwide, mostly from a caesium-bearing mineral pollucite.

<span class="mw-page-title-main">Isotopes of iodine</span> Nuclides with atomic number of 53 but with different mass numbers

There are 37 known isotopes of iodine (53I) from 108I to 144I; all undergo radioactive decay except 127I, which is stable. Iodine is thus a monoisotopic element.

Caesium (55Cs) has 40 known isotopes, making it, along with barium and mercury, one of the elements with the most isotopes. The atomic masses of these isotopes range from 112 to 151. Only one isotope, 133Cs, is stable. The longest-lived radioisotopes are 135Cs with a half-life of 2.3 million years, 137
Cs
with a half-life of 30.1671 years and 134Cs with a half-life of 2.0652 years. All other isotopes have half-lives less than 2 weeks, most under an hour.

Selenium (34Se) has six natural isotopes that occur in significant quantities, along with the trace isotope 79Se, which occurs in minute quantities in uranium ores. Five of these isotopes are stable: 74Se, 76Se, 77Se, 78Se, and 80Se. The last three also occur as fission products, along with 79Se, which has a half-life of 327,000 years, and 82Se, which has a very long half-life (~1020 years, decaying via double beta decay to 82Kr) and for practical purposes can be considered to be stable. There are 23 other unstable isotopes that have been characterized, the longest-lived being 79Se with a half-life 327,000 years, 75Se with a half-life of 120 days, and 72Se with a half-life of 8.40 days. Of the other isotopes, 73Se has the longest half-life, 7.15 hours; most others have half-lives not exceeding 38 seconds.

Californium (98Cf) is an artificial element, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no stable isotopes. The first isotope to be synthesized was 245Cf in 1950. There are 20 known radioisotopes ranging from 237Cf to 256Cf and one nuclear isomer, 249mCf. The longest-lived isotope is 251Cf with a half-life of 898 years.

Cesium_137 is an American futurepop musical group composed of Isaac Glendening and Vince Guzzardo. It originally also included Matt Cargill.

<span class="mw-page-title-main">Caesium-137</span> Radioactive isotope of caesium

Caesium-137, cesium-137 (US), or radiocaesium, is a radioactive isotope of caesium that is formed as one of the more common fission products by the nuclear fission of uranium-235 and other fissionable isotopes in nuclear reactors and nuclear weapons. Trace quantities also originate from spontaneous fission of uranium-238. It is among the most problematic of the short-to-medium-lifetime fission products. Caesium-137 has a relatively low boiling point of 671 °C (1,240 °F) and is volatilized easily when released suddenly at high temperature, as in the case of the Chernobyl nuclear accident and with atomic explosions, and can travel very long distances in the air. After being deposited onto the soil as radioactive fallout, it moves and spreads easily in the environment because of the high water solubility of caesium's most common chemical compounds, which are salts. Caesium-137 was discovered by Glenn T. Seaborg and Margaret Melhase.

Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.

<span class="mw-page-title-main">Strontium-90</span> Radioactive isotope of strontium

Strontium-90 is a radioactive isotope of strontium produced by nuclear fission, with a half-life of 28.8 years. It undergoes β decay into yttrium-90, with a decay energy of 0.546 MeV. Strontium-90 has applications in medicine and industry and is an isotope of concern in fallout from nuclear weapons, nuclear weapons testing, and nuclear accidents.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

<span class="mw-page-title-main">Prostate brachytherapy</span> Radiation therapy technique for the treatment of cancer

Brachytherapy is a type of radiotherapy, or radiation treatment, offered to certain cancer patients. There are two types of brachytherapy – high dose-rate (HDR) and low dose-rate (LDR). LDR brachytherapy is the one most commonly used to treat prostate cancer. It may be referred to as 'seed implantation' or it may be called 'pinhole surgery'.

Docrates Cancer Center is the first and currently the only private hospital in the Nordic countries that comprehensively specialises in cancer treatment. It operates in Helsinki, Finland. It characterises its operations as those complementing the public sector. Docrates Oy was established in 2006 and the hospital started its operations at the premises of Eira Hospital in autumn 2007. It moved to its own premises in Jätkäsaari, Helsinki, in 2009, where it has hospital rights. There is a ward and Health and Recovery Center located at Docrates Cancer Center. Among other things, diagnostics, pharmacotherapy, radiation therapy and isotopic treatments are carried out at the hospital. Cancer surgeries are performed in partner hospitals. Docrates also participates in clinical trials and the testing and development of new treatments.

<span class="mw-page-title-main">Radiopharmaceutical</span> Pharmaceutical drug which emits radiation, used as a diagnostic or therapeutic agent

Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.

<span class="mw-page-title-main">Margaret Melhase</span> American chemistry student and a co-discoverer of caesium-137

Margaret Melhase Fuchs was an American chemist and a co-discoverer, with Glenn T. Seaborg, of the isotope caesium-137.

References

Notes
  1. "About Isoray - Personalized Brachytherapy Products".
  2. "Cesium Blu by Isoray - Treating Prostate Cancer with Brachytherapy".
  3. 1 2 "Investor FAQ".